



Press Release 26th of May 2010

Change in number of shares in BioGaia AB

Redemption of warrants during May has led to an increase of BioGaia's share capital by SEK 3,000 to a total of SEK 17,210,562. The number of shares has increased by 3,000 B shares to a total of 740,668 A shares and 16,469,894 B shares which is equal to 23,876,574 votes.

In June 2007, BioGaia carried out a warrant programme approved by the AGM the same year. A total of 128 950 options were subscribed for by the employees (of which 27 000 by the management). Each warrant grants the holder the right to subscribe for one class B share for SEK 76.70 during the period from 15 May 2010 to 31 August 2010.

For additional information contact:

Peter Rothschild, President, telephone: +46 8 -555 293 00
Margareta Hagman, Executive Vice President, telephone: +46 8-555 293 00

Latest press releases from BioGaia:

2010-05-10	New Reuteri study published: <i>L. reuteri</i> Protectis reduced gastrointestinal symptoms and hospital stay in premature newborns
2010-05-07	Annual General Meeting of BioGaia
2010-05-06	BioGaia AB Interim Report 1 January - 31 March 2010

***BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium *Lactobacillus reuteri* (Reuteri), which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm.
www.biogaia.com***